Alpha-santalol inhibited migration of breast cancer cells may be mediated, in part, by targeting Wnt//β-catenin pathway. β-catenin represents an important target of α-santalol's response for future pre-clinical studies.
Background: Enoxaparin is commonly used for venous thromboembolism (VTE) prophylaxis in hospitalized patients. Published literature exists for dose adjustment in higher body weights and renal dysfunction, but sparse literature on optimal dosing of prophylactic enoxaparin in underweight patients exists. Objective: To determine if there is a difference in adverse outcomes or effectiveness if enoxaparin VTE prophylaxis dosing is reduced to 30 mg subcutaneously once daily from standard dosing in underweight medically ill patients. Methods: This study was a retrospective chart review of a total of 171 patients, with 190 individual courses of enoxaparin included. Patients were ≥18 years of age, weighed ≤50 kg, and were given at least 2 days of consecutive therapy. Patients were excluded if they were taking anticoagulation upon admission, had a creatinine clearance <30 mL/min, were admitted to the ICU or a trauma or surgical service, or presented with bleeding or thrombosis. The Padua score and a modified score from the IMPROVE trial were used to evaluate baseline thrombotic risk and bleeding risk, respectively. Bleeding events were classified using the Bleeding Academic Research Consortium criteria. Results: No difference was seen in baseline risk of bleeding or thrombosis when comparing the reduced and standard dosing groups. No differences were observed with rates of bleeding, thrombotic events, mortality, or 30-day readmission. Conclusion: Both reduced and standard dosing strategies appeared effective for VTE prophylaxis, but neither showed superiority in reducing bleeding events. Additional larger studies are needed to evaluate safety and effectiveness of reduced dose of enoxaparin in this patient population.
Alpha-santalol, a terpenoid found in sandalwood oil has been shown to inhibit breast cancer cell growth in vitro by inducing apoptosis but the mechanisms underlying the growth inhibitory effects of alpha-santalol are not fully understood. In this study, we demonstrate that alpha-santalol treatment targets Wnt/beta-catenin pathway to inhibit migration of cultured breast cancer cells. Exposure of MDA-MB 231 and MCF-7 cells to alpha-santalol resulted in a significant reduction in their migratory potential and wound healing ability. In addition alpha-santalol affected the localization of beta-catenin from cytosol to nucleus in MDA-MB 231 cells. In conclusion, the present study indicates that alpha-santalol inhibited migration of breast cancer cells may be mediated in part by targeting Wnt//β-catenin pathway, and that beta-catenin represents an important target of alpha-santalol’s response for future pre-clinical studies.
Citation Format: Ajay Bommareddy, Kacey Knapp, Abigail Nemeth, Chandradhar Dwivedi. Alpha -Santalol, a component of sandalwood oil inhibits migration of breast cancer cells by targeting beta-catenin pathway [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 649.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.